Literature DB >> 26567228

Evidence of microvascular dysfunction in heart failure with preserved ejection fraction.

Joshua F Lee1, Zachary Barrett-O'Keefe2, Ryan S Garten1, Ashley D Nelson3, John J Ryan4, Jose N Nativi4, Russell S Richardson5, D Walter Wray5.   

Abstract

OBJECTIVE: While vascular dysfunction is well defined in patients with heart failure (HF) with reduced ejection fraction (HFrEF), disease-related alterations in the peripheral vasculature of patients with HF with preserved ejection fraction (HFpEF) are not well characterised. Thus, we sought to test the hypothesis that patients with HFpEF would demonstrate reduced vascular function, at the conduit artery and microvascular levels, compared with controls.
METHODS: We examined conduit artery function via brachial artery flow-mediated dilation (FMD) and microvascular function via reactive hyperaemia (RH) following 5 min of ischaemia in 24 patients with Class II-IV HFpEF and 24 healthy controls matched for age, sex and brachial artery diameter.
RESULTS: FMD was reduced in patients with HFpEF compared with controls (HFpEF: 3.1±0.7%; CONTROLS: 5.1±0.5%, p=0.03). However, shear rate at time of peak brachial artery dilation was lower in patients with HFpEF compared with controls (HFpEF: 42 070±4018/s; CONTROLS: 69 018±9509/s, p=0.01), and when brachial artery FMD was normalised for the shear stimulus, cumulative area-under-the-curve (AUC) at peak dilation, the between-group differences were eliminated (HFpEF: 0.11±0.03%/AUC; CONTROLS: 0.09±0.01%/AUC, p=0.58). RH, assessed as AUC, was lower in patients with HFpEF (HFpEF: 454±35 mL; CONTROLS: 660±63 mL, p<0.01).
CONCLUSIONS: Collectively, these data suggest that maladaptations at the microvascular level contribute to the pathophysiology of HFpEF, while conduit artery vascular function is not diminished beyond that which occurs with healthy aging. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Mesh:

Year:  2015        PMID: 26567228      PMCID: PMC4866903          DOI: 10.1136/heartjnl-2015-308403

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  30 in total

Review 1.  Mechanisms of exercise intolerance in heart failure with preserved ejection fraction.

Authors:  Barry A Borlaug
Journal:  Circ J       Date:  2013-12-03       Impact factor: 2.993

2.  Endothelial dysfunction, measured by reactive hyperaemia using strain-gauge plethysmography, is an independent predictor of adverse outcome in heart failure.

Authors:  José R de Berrazueta; Armando Guerra-Ruiz; María Teresa García-Unzueta; Gema Martín Toca; Rocío Sainz Laso; María Sáez de Adana; Miguel A Casanova Martín; Manuel Cobo; Javier Llorca
Journal:  Eur J Heart Fail       Date:  2010-03-30       Impact factor: 15.534

3.  Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: the role of abnormal peripheral oxygen extraction.

Authors:  Bishnu P Dhakal; Rajeev Malhotra; Ryan M Murphy; Paul P Pappagianopoulos; Aaron L Baggish; Rory B Weiner; Nicholas E Houstis; Aaron S Eisman; Stacyann S Hough; Gregory D Lewis
Journal:  Circ Heart Fail       Date:  2014-10-24       Impact factor: 8.790

4.  Endothelial dysfunction measured by peripheral arterial tonometry predicts prognosis in patients with heart failure with preserved ejection fraction.

Authors:  Yuya Matsue; Makoto Suzuki; Wataru Nagahori; Masakazu Ohno; Akihiko Matsumura; Yuji Hashimoto; Kazuki Yoshida; Masayuki Yoshida
Journal:  Int J Cardiol       Date:  2012-09-27       Impact factor: 4.164

5.  Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction.

Authors:  Barry A Borlaug; Thomas P Olson; Carolyn S P Lam; Kelly S Flood; Amir Lerman; Bruce D Johnson; Margaret M Redfield
Journal:  J Am Coll Cardiol       Date:  2010-09-07       Impact factor: 24.094

6.  Outcome of heart failure with preserved ejection fraction in a population-based study.

Authors:  R Sacha Bhatia; Jack V Tu; Douglas S Lee; Peter C Austin; Jiming Fang; Annick Haouzi; Yanyan Gong; Peter P Liu
Journal:  N Engl J Med       Date:  2006-07-20       Impact factor: 91.245

7.  Systolic and diastolic heart failure in the community.

Authors:  Francesca Bursi; Susan A Weston; Margaret M Redfield; Steven J Jacobsen; Serguei Pakhomov; Vuyisile T Nkomo; Ryan A Meverden; Véronique L Roger
Journal:  JAMA       Date:  2006-11-08       Impact factor: 56.272

8.  Vascular function and the role of oxidative stress in heart failure, heart transplant, and beyond.

Authors:  Melissa A H Witman; Anette S Fjeldstad; John McDaniel; Stephen J Ives; Jia Zhao; Zachary Barrett-O'Keefe; Jose N Nativi; Josef Stehlik; D Walter Wray; Russell S Richardson
Journal:  Hypertension       Date:  2012-07-02       Impact factor: 10.190

9.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.

Authors:  Salim Yusuf; Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

10.  Irbesartan in patients with heart failure and preserved ejection fraction.

Authors:  Barry M Massie; Peter E Carson; John J McMurray; Michel Komajda; Robert McKelvie; Michael R Zile; Susan Anderson; Mark Donovan; Erik Iverson; Christoph Staiger; Agata Ptaszynska
Journal:  N Engl J Med       Date:  2008-11-11       Impact factor: 91.245

View more
  38 in total

Review 1.  Deep Phenotyping of Systemic Arterial Hemodynamics in HFpEF (Part 2): Clinical and Therapeutic Considerations.

Authors:  Julio A Chirinos
Journal:  J Cardiovasc Transl Res       Date:  2017-04-11       Impact factor: 4.132

2.  Effect of Heart Failure With Preserved Ejection Fraction on Nitric Oxide Metabolites.

Authors:  Payman Zamani; Benjamin French; Jeffrey A Brandimarto; Paschalis-Thomas Doulias; Ali Javaheri; Julio A Chirinos; Kenneth B Margulies; Raymond R Townsend; Nancy K Sweitzer; James C Fang; Harry Ischiropoulos; Thomas P Cappola
Journal:  Am J Cardiol       Date:  2016-09-15       Impact factor: 2.778

Review 3.  Flow-mediated dilation stimulated by sustained increases in shear stress: a useful tool for assessing endothelial function in humans?

Authors:  Joshua C Tremblay; Kyra E Pyke
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-11-22       Impact factor: 4.733

4.  Impact of Exercise Training on Peak Oxygen Uptake and its Determinants in Heart Failure with Preserved Ejection Fraction.

Authors:  Wesley J Tucker; Michael D Nelson; Rhys I Beaudry; Martin Halle; Satyam Sarma; Dalane W Kitzman; Andre La Gerche; Mark J Haykowksy
Journal:  Card Fail Rev       Date:  2016-11

5.  Cardiovascular responses to rhythmic handgrip exercise in heart failure with preserved ejection fraction.

Authors:  Stephen M Ratchford; Heather L Clifton; D Taylor La Salle; Ryan M Broxterman; Joshua F Lee; John J Ryan; Paul N Hopkins; Josephine B Wright; Joel D Trinity; Russell S Richardson; D Walter Wray
Journal:  J Appl Physiol (1985)       Date:  2020-09-17

6.  Einstein, the Blind Men, and the Elephant: Making Sense of Heart Failure With Preserved Ejection Fraction.

Authors:  Scott L Hummel
Journal:  J Card Fail       Date:  2016-10-17       Impact factor: 5.712

Review 7.  Current Perspectives on Systemic Hypertension in Heart Failure with Preserved Ejection Fraction.

Authors:  Marty C Tam; Ran Lee; Thomas M Cascino; Matthew C Konerman; Scott L Hummel
Journal:  Curr Hypertens Rep       Date:  2017-02       Impact factor: 5.369

Review 8.  Relative Impairments in Hemodynamic Exercise Reserve Parameters in Heart Failure With Preserved Ejection Fraction: A Study-Level Pooled Analysis.

Authors:  Ambarish Pandey; Rohan Khera; Bryan Park; Mark Haykowsky; Barry A Borlaug; Gregory D Lewis; Dalane W Kitzman; Javed Butler; Jarett D Berry
Journal:  JACC Heart Fail       Date:  2018-02       Impact factor: 12.035

9.  Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF.

Authors:  Sanjiv J Shah; Carolyn S P Lam; Sara Svedlund; Antti Saraste; Camilla Hage; Ru-San Tan; Lauren Beussink-Nelson; Ulrika Ljung Faxén; Maria Lagerström Fermer; Malin A Broberg; Li-Ming Gan; Lars H Lund
Journal:  Eur Heart J       Date:  2018-10-01       Impact factor: 29.983

Review 10.  Flow-mediated dilation and heart failure: a review with implications to physical rehabilitation.

Authors:  G P T Areas; A Mazzuco; F R Caruso; R B Jaenisch; R Cabiddu; S A Phillips; R Arena; A Borghi-Silva
Journal:  Heart Fail Rev       Date:  2019-01       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.